Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study
- 1 December 2018
- journal article
- research article
- Published by Elsevier BV in Pulmonary Pharmacology & Therapeutics
- Vol. 53, 1-5
- https://doi.org/10.1016/j.pupt.2018.09.006
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Update on Anticytokine Treatment for AsthmaBioMed Research International, 2013
- The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysisJournal of Allergy and Clinical Immunology, 2013
- Targeting eosinophils in allergy, inflammation and beyondNature Reviews Drug Discovery, 2013
- The potential of biologics for the treatment of asthmaNature Reviews Drug Discovery, 2012
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Mepolizumab for Prednisone-Dependent Asthma with Sputum EosinophiliaThe New England Journal of Medicine, 2009
- A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Severe exacerbations predict excess lung function decline in asthmaEuropean Respiratory Journal, 2007
- Interleukin-5 Induces CD34+ Eosinophil Progenitor Mobilization and Eosinophil CCR3 Expression in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Eosinophilic Inflammation in AsthmaThe New England Journal of Medicine, 1990